Elongated tissue matrices

Patent metadata

Field	Value
Publication number	US-10327884-B2
Application number	US-201615003187-A
Country	US
Kind code	B2
Filing date	Jan 21, 2016
Priority date	Jan 24, 2012
Publication date	Jun 25, 2019
Grant date	Jun 25, 2019

Abstract

Elongated and high aspect ratio tissue treatment products are provided. Methods of making and using the tissue treatment products are also provided. The tissue treatment products can be used as implants that conform to the site of implantation and resist migration away from their implantation site in vivo.

First claim

What is claimed is:

1. A tissue treatment composition comprising:
a collection of loosely arranged elongated elements, each elongated element comprising a tissue matrix that has been at least partially decellularized, wherein each elongated element has a flexible three-dimensional structure comprising a length dimension, a width dimension, and a height dimension, and wherein each elongated element has an aspect ratio greater than 50:1, wherein the collection of loosely arranged elongated elements are configured to be implanted into an anatomical site such that the tissue matrix is in direct contact with surrounding native tissue thereby allowing cellular ingrowth and tissue integration.

2. The composition of claim 1 , wherein each elongated element is in the form of a cylinder.

3. The composition of claim 1 , wherein each elongated element has an aspect ratio greater than 100:1.

4. The composition of claim 1 , wherein the elongated elements comprise partially or fully decellularized tissue matrix from at least one of human, nonhuman primate, pig, cow, horse, goat, sheep, dog, cat, rabbit, guinea pig, gerbil, hamster, rat, and mouse tissue.

5. The composition of claim 4 , wherein the elongated elements comprise at least one porcine acellular tissue matrix.

6. The composition of claim 1 , wherein the elongated elements comprise partially or fully decellularized tissue matrix from at least one of bone, skin, dermis, intestine, vascular, urinary bladder, tendon, ligament, muscle, fascia, neurologic tissue, vessel, liver, heart, lung, kidney, or cartilage tissue.

7. The composition of claim 6 , wherein the elongated elements comprise dermal acellular tissue matrix.

8. The composition of claim 1 , wherein the elongated elements lack substantially all alpha-galactose moieties.

9. The composition of claim 1 , further comprising one or more viable and histocompatible cells.

10. The composition of claim 9 , wherein the one or more cells are mammalian cells.

11. The composition of claim 9 , wherein the one or more cells are stem cells.

Assignees

• Lifecell Corp

Inventors

• Roock Timothy
• Bachrach Nathaniel
• Kibalo Benjamin T

Classifications

• A61L27/38

  containing added animal cells (organs or tissue containing native cells A61L27/36) · CPC title

• A61L27/362

  Skin, e.g. dermal papillae · CPC title

• A61L27/3683

  subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment · CPC title

• A61L2430/40

  Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking · CPC title

• A61L2400/06

  Flowable or injectable implant compositions · CPC title